Beyond therapeutics, monoclonal antibodies shown to be effective in the clinic can help to facilitate laboratory research. Researchers use mAbs, also known as biosimilars, as tools to research novel therapies and uncover effective off-target applications. With known and approved data on toxicity and efficacy, researchers use these biologics as benchmarks in their studies, allowing them to accelerate their findings from bench to clinic.
ProSci offers more than 800 research-grade biosimilar antibodies in the following research areas: cancer, pain, blood-related diseases, bacterial infection, neurodegenerative, asthma, psoriasis and other dermatitis, rheumatoid arthritis and osteoporosis, inflammatory diseases, Crohn’s disease, virus infection, and diabetes and other autoimmune diseases.
Phone: 02 9698 2022
BioStatus CyTRAK Orange fluorescent dye
BioStatus's CyTRAK Orange is a novel fluorescent dye that preferentially stains the nucleus...
Bio-Rad Laboratories anti-idiotypic antibodies and Human IgM-FcSpyCatcher reagent
Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies...
ProSci Incorporated apoptosis antibodies
ProSci Incorporated provides an extensive catalogue of apoptotic antibodies including death...
